In Vitro Sensitivity of Probiotics to Human Pancreatic Juice

2008 ◽  
Vol 42 ◽  
pp. S170-S173 ◽  
Author(s):  
Mario Del Piano ◽  
Paolo Strozzi ◽  
Michela Barba ◽  
Serena Allesina ◽  
Francesca Deidda ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
In Vitro Sensitivity

PA.184 IN VITRO SENSITIVITY OF PROBIOTICS TO HUMAN PANCREATIC JUICE

2008 ◽  
Vol 40 ◽  
pp. S143
Author(s):  
S. Carmagnola ◽  
G.P. Strozzi ◽  
M. Barba ◽  
S. Allesina ◽  
M. Ballarè ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
In Vitro Sensitivity

scholarly journals In Vitro Sensitivity to Antibiotics of Swedish Strains of Mycoplasma Gallisepticum

1965 ◽  
Vol 6 (1) ◽  
pp. 234-238
Author(s):  
Lena Silvén
Keyword(s):  
Mycoplasma Gallisepticum ◽  
In Vitro Sensitivity

In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration

2021 ◽  
Vol 18 (4) ◽  
pp. 1711-1719
Author(s):  
Toshihide Takagi ◽  
Takato Masada ◽  
Keiko Minami ◽  
Makoto Kataoka ◽  
Ken-ichi Izutsu ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Oral Administration ◽  
Dissolution Profile ◽  
Basic Drugs ◽  
Plasma Exposure ◽  
In Vitro Sensitivity

scholarly journals Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border

2014 ◽  
Vol 13 (1) ◽  
pp. 23 ◽  
Author(s):  
Papichaya Phompradit ◽  
Poonuch Muhamad ◽  
Raewadee Wisedpanichkij ◽  
Wanna Chaijaroenkul ◽  
Kesara Na-Bangchang
Keyword(s):  
Plasmodium Falciparum ◽  
Molecular Markers ◽  
In Vitro Sensitivity

Ornidazole and Anaerobic Bacteria: In Vitro Sensitivity and Effects on Wound Infections after Appendectomy

1979 ◽  
Vol 139 (5) ◽  
pp. 586-589 ◽  
Author(s):  
A. Palmu ◽  
O.-V. Renkonen ◽  
U. Aromaa
Keyword(s):  
Anaerobic Bacteria ◽  
Wound Infections ◽  
In Vitro Sensitivity

Functional precision medicine in colorectal cancer based on patient-derived tumoroids and in-vitro sensitivity drug testing.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15567-e15567
Author(s):  
Lars Henrik Jensen ◽  
Anders Kristian Moeller Jakobsen ◽  
Birgitte Mayland Havelund ◽  
Cecilie Abildgaard ◽  
Chris Vagn-Hansen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Primary Endpoint ◽  
Drug Testing ◽  
Progression Free Survival ◽  
Patient Specific ◽  
Precision Oncology ◽  
Sensitivity Testing ◽  
In Vitro Sensitivity

e15567 Background: Precision oncology based on in-vitro, functional assays has potential advantages compared to the much more common molecular approach, but the clinical benefit is unknown. We here report the results from the largest prospective interventional clinical trial testing the clinical outcome in colorectal cancer patients treated with drugs showing cytotoxic effect in matched patient-derived tumoroids. Methods: This single-center, phase II trial included patients with metastatic colorectal cancer previously exposed to all standard therapies. Specimens from one to three 18-16 G core needle biopsies were manually dissected, enzymatically treated, cultivated, and incubated to form 3D spherical microtumors, i.e. tumoroids. In the assay for in-vitro sensitivity testing, the tumoroids were challenged with single drugs and combinations thereof to determine patient-specific responses. Using tumoroid screening technology (IndiTreat, 2cureX, Copenhagen, Denmark), results were generated by comparing the sensitivity of the individual patient’s tumoroids with a reference panel from other patients. The testing included standard cytostatics and drugs with proven effect in previous early-phase clinical trials, a total of 15 drugs. The primary endpoint was the fraction of patients with progression-free survival (PFS) at two months. Based on placebo arms in randomized last-line trials, a minimal relevant difference of 20% (20% to 40%) was stated. Using Simon's two-stage design, a sample size of 45 patients was calculated with at least 14 PFS at two months (significance 5%, power 90%). Results: Ninety patients were enrolled from 9/2017 to 9/2020. Biopsies from 82 patients were obtained and sent for tumoroid formation of which 44 (54%, 95% CI 42-65) were successful and at least one treatment was suggested. Thirty-four patients initiated treatment according to the response obtained in the drug assays within a median of 51 days from inclusion (IQR 39-63). The primary endpoint, PFS at two months, was met in 17 of 34 patients (50%, 95%CI 32-68). There were no radiological responses. Median PFS was 81 days (95% CI 51-112) and median OS was 189 days (95% CI 103-277). Conclusions: Precision oncology using a functional approach with patient-derived tumoroids and in-vitro drug sensitivity testing seems feasible. The approach is limited by the fraction of patients with successful tumoroid development. The primary endpoint was met, as half of the patients were without progression at two months. Further clinical studies are justified. Clinical trial information: NCT03251612.

scholarly journals ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer

2010 ◽  
Vol 1 (2) ◽  
pp. 279-282 ◽  
Author(s):  
YOSHIMASA INOUE ◽  
HOZUMI MATSUMOTO ◽  
SHUNSUKE YAMADA ◽  
KENJI KAWAI ◽  
HIROSHI SUEMIZU ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
In Vitro Sensitivity

Study Of The In-Vitro Sensitivity Of Meningococci And Its Implications In Prophylaxis

1973 ◽  
Vol 28 (5) ◽  
pp. 281-286
Author(s):  
E. Yourassowsky ◽  
E. Schoutens ◽  
M.P. Vanderlinden
Keyword(s):  
In Vitro Sensitivity

scholarly journals In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.

1997 ◽  
Vol 41 (4) ◽  
pp. 827-830 ◽  
Author(s):  
F Faraut-Gambarelli ◽  
R Piarroux ◽  
M Deniau ◽  
B Giusiano ◽  
P Marty ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Leishmania Infantum ◽  
Strongly Correlated ◽  
Duration Of Treatment ◽  
In Vitro Sensitivity ◽  
Sensitivity Tests ◽  
Leishmania Parasites ◽  
Immunocompetent Patients

Primary and secondary unresponsiveness to meglumine has long been described in human visceral leishmaniasis. However, no studies have been performed to elucidate if these therapeutic failures were due to strain variability in meglumine sensitivity or were related to host factors. We have studied the in vitro sensitivity of 37 strains of Leishmania infantum isolated from 23 patients (11 human immunodeficiency virus-infected and 12 immunocompetent patients) with visceral leishmaniasis. Sensitivity tests were performed by infecting murine macrophages with Leishmania parasites and culturing them in medium containing different concentrations of meglumine. For each test we calculated a 50% effective dose (ED50) corresponding to the meglumine concentration at which 50% of the Leishmania parasites survived. In vitro results were strongly correlated to immediate clinical outcome. All strains requiring an ED50 of >70 microg/ml were related to therapeutic failures, whereas all strains requiring an ED50 of <40 microg/ml corresponded to an initial efficiency of meglumine. Among those patients who were initially improved, relapses occurred in all immunocompromised patients and in most immunocompetent patients who had a short duration of treatment (15 days). Finally, we found that in vitro sensitivity of strains decreased progressively in relapsing patients treated with meglumine. Consequently, the physician may be encouraged to alternate meglumine with other treatments such as amphotericin B or pentamidine, especially in the case of relapsing patients.

Sign in / Sign up

Export Citation Format

Share Document